后巴罗破裂动脉瘤试验时代的囊状动脉瘤
该单中心回顾性队列研究纳入2007年8月1日至2019年7月31日治疗的798例囊状动脉瘤性蛛网膜下腔出血患者,比较显微手术与血管内治疗。随访≥1年时两组神经功能结局无差异(p=0.51),血管内治疗组再治疗率显著更高(9% vs 1%,p<0.001),但血管内治疗后再治疗率低于原巴罗破裂动脉瘤试验的18%。
要点
- 显微手术组与血管内治疗组随访≥1年神经功能结局无差异(p=0.51)。
- 血管内治疗组再治疗率显著高于显微手术组(9% vs 1%,p<0.001)。
- 后巴罗时代血管内治疗后再治疗率(9%)低于原试验(18%)。
核心结论
- 后巴罗时代结果显示显微手术与血管内栓塞的神经功能结局相当,但血管内治疗组再治疗率更高。
- 血管内治疗后再治疗率在后巴罗时代远低于原巴罗破裂动脉瘤试验。
研究设计与样本
- 回顾性队列研究,单中心四级中心,纳入2007年8月1日至2019年7月31日经脑血管专家确诊的囊状动脉瘤性蛛网膜下腔出血患者。
- 共1014例动脉瘤性蛛网膜下腔出血患者,其中798例(79%)确诊为囊状动脉瘤,按接受显微手术(n=451)或血管内治疗(n=347)分为两组比较。
主要发现
- 随访≥1年时,显微手术组(n=451)与血管内治疗组(n=347)的神经功能不良结局(改良Rankin量表评分>2)无差异(p=0.51)。
- 血管内治疗组再治疗数为32/347(9%),显微手术组为6/451(1%),血管内治疗组显著更高(p<0.001)。
- 血管内治疗后再治疗率在后巴罗时代为9%,低于原巴罗破裂动脉瘤试验的18%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Barrow Ruptured Aneurysm Trial (BRAT) was a single-center trial that compared endovascular coiling to microsurgical clipping in patients treated for aneurysmal subarachnoid hemorrhage (aSAH). However, because patients in the BRAT were treated more than 15 years ago, and because there have been advances since then-particularly in endovascular techniques-the relevance of the BRAT today remains controversial. Some hypothesize that these technical advances may reduce retreatment rates for endovascular intervention. In this study, the authors analyzed data for the post-BRAT (PBRAT) era to compare microsurgical clipping with endovascular embolization (coiling and flow diverters) in the two time periods and to examine how the results of the original BRAT have influenced the practice of neurosurgeons at the study institution. METHODS: In this retrospective cohort study, the authors evaluated patients with saccular aSAHs who were treated at a single quaternary center from August 1, 2007, to July 31, 2019. The saccular aSAH diagnoses were confirmed by cerebrovascular experts. Patients were separated into two cohorts for comparison on the basis of having undergone microsurgery or endovascular intervention. The primary outcome analyzed for comparison was poor neurological outcome, defined as a modified Rankin Scale (mRS) score > 2. The secondary outcomes that were compared included retreatment rates for both therapies. RESULTS: Of the 1014 patients with aSAH during the study period, 798 (79%) were confirmed to have saccular aneurysms. Neurological outcomes at ≥ 1-year follow-up did not differ between patients treated with microsurgery (n = 451) and those who received endovascular (n = 347) treatment (p = 0.51). The number of retreatments was significantly higher among patients treated endovascularly (32/347, 9%) than among patients treated microsurgically (6/451, 1%) (p < 0.001). The retreatment rate after endovascular treatment was lower in the PBRAT era (9%) than in the BRAT (18%). CONCLUSIONS: Similar to results from the BRAT, results from the PBRAT era showed equivalent neurological outcomes and increased rates of retreatment among patients undergoing endovascular embolization compared with those undergoing microsurgery. However, the rate of retreatment after endovascular intervention was much lower in the PBRAT era than in the BRAT.
引用
- Catapano JS, Labib MA, Srinivasan VM, et al. Saccular aneurysms in the post-Barrow Ruptured Aneurysm Trial era. J Neurosurg. 2021. PMID: 34826811. doi:10.3171/2021.8.JNS211060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。